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Background: Trastuzumab was licensed for adjuvant therapy in
early breast cancer (EBC) in the UK in 2006. The objectives of this
multicentre audit were to determine the incidence of HER2+
breast cancers, proportion of HER2+ EBC women who received
Trastuzumab and ascertain reasons why some HER2+ patients
did not receive Trastuzumab.
Methods: Data collected for all invasive breast cancers diag-
nosed at seven UK centres over 18-months from 2007 onwards.
All HER2+ cancers diagnosed by a combination of IHC and FISH
identified using each centre’s database. Case records checked
and reasons noted if they had not received Trastuzumab.
Results: Patients (4488) diagnosed with invasive breast cancer.
645 (14%) were HER2+ cancers, 523 being EBCs. 326 (62%) HER2+
EBCs received Trastuzumab.
Reasons for not receiving Trastuzumab n = 197(%)
Tumour 610 mm, node negative 65(33)
Small node negative tumours (11–20 mm) 18(9)
Age 42(21)
Comorbidities 27(13)
Therapy refused 28(14)
Other reasons 17(9)
Conclusions: Incidence of HER2+ breast cancers is 14%, majority
being EBCs (81%). Only 62% of the HER2+ EBC patients received
Trastuzumab. Whilst the commonest reason for not receiving
Trastuzumab is small node negative tumours (which is compatible
with UK guidelines), an equal number of patients potentially
missed optimal therapy for reasons not noted in the guidelines.
Recent studies havedemonstrated that beingHER2+ is a significant
risk factor for relapse in patients previously perceived to be at low
risk and no HER2+ patient should now be considered low risk.1
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Objective: Of the 49,452 breast cancers diagnosed in the UK in
2006, 25,049 (51%) were diagnosed symptomatically in patients
aged 50 and over. This study compares the nature and treatment
of symptomatic invasive cancers in patients aged 50–69 and 70
years or over (‘elderly’).
Methods: Data were extracted from national audit databases
and from the merged cancer registry database linked to HES.
Results: 84% of Patients aged 50–69 had surgery recorded
compared with 55% of patients aged 70 or over. Surgery rates
increased to 79% in ‘elderly’ patients known to be ER negative.
‘Elderly’ patients were more likely to have a mastectomy (61%
versus 50%). For surgically treated tumours, prognostic factors
were similar in both groups: node positivity: 54% in 50–69 ver-
sus 50% in ‘elderly’, ER status (73% ER positive in 50–69 versus
77% in ‘elderly’) and grade (52% Grade 1 or 2 in 50–69 versus
59% in ‘elderly’). For cases with adjuvant therapy data avail-
able, radiotherapy after conserving surgery was slightly lower
in the ‘elderly’ (87% versus 94%), chemotherapy for node posi-
tive patients was much lower in the ‘elderly’ (21% versus 75%)
and more ‘elderly’ patients received hormone therapy (90%
versus 83%).
Conclusion: ‘Elderly’ patients were less likely to receive surgery
or chemotherapy. Patient choice, the presence of co-morbidities,
lack of evidence on the relative risks/benefits of adjuvant therapy
or reduced access to surgery for older patients are factors which
might explain the differential treatment of these patients.
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Background: Breast cancer relative survival (BCRS) tends to be
poorer in older women, but the reasons for this are not clear.
We examined the influence of patient and tumour characteristics,
and treatment on BCRS to see if these could explain the age spe-
cific effects.
Methodology: Data for 14,048 female breast cancer patients
diagnosed from 1999 to 2007 aged 50 years or over were obtained
from the Eastern Cancer Registration and Information Centre. We
estimated relative 5- and 10-year survival for patients in four age
groups (50–69, 70–74, 75–79, and 80+). We also modelled relative
excess mortality rate (REM) adjusting for potential confounders.
Covariates included in the analysis were age, TNM stage, histo-
logic grade, ER status, mode of detection, volume at hospital of
diagnosis, and treatment (surgery, radiotherapy, chemotherapy
and hormonal therapy.
Results: Median follow-up time was 4.7 years. Relative 5-
year survival was 90%, 81%, 76% and 68% for patients aged
50–69, 70–74, 75–79 and 80+, respectively. Corresponding rela-
tive 10-year survival was 84%, 77%, 66% and 60%. Similar pat-
terns were seen for both ER+ and ER and for low and high
volume hospitals.
Unadjusted REM was 1.95, 2.86 and 4.30 for patients aged 70–
74, 75–79 and 80+, respectively (50–69 reference). These were
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